Role of DNA Methylation for diagnosis and clinical management in neuro-oncology
This course will discuss principles of DNA methylation and suitability for routine brain tumor diagnostics. An overview of the method, and impact on accurate diagnostics for newly diagnosed and recurrent tumors will be presented. Furthermore, the role of DNA methylation in avoiding diagnostic errors and accurately diagnose brain tumors, which were unclassifiable using routine diagnostic tools will be discussed.
Adult and pediatric neuro-oncologists, neurosurgeons and nurse practitioners, social workers and caregivers of patients with primary brain tumors, pathologists.
- The principles of molecular diagnostics using DNA methylation and machine learning
- The role of DNA methylation-based classification for accurate diagnostics and clinical management of patients with primary brain tumors
- How to integrate DNA methylation in routine clinical testing
Matija Snuderl, MD
NYU Langone Health
Dr. Snuderl is Associate Professor of Pathology and Director of the Molecular Pathology and Diagnostics at NYU Langone Health. Dr. Snuderl was born in Slovenia and obtained his MD degree from Charles University, Prague and completed his residency in Anatomic Pathology and Neuropathology at Massachusetts General Hospital. He then completed fellowship in Molecular Genetic Pathology at Harvard Medical School and post-doctoral fellowship at the Edwin L. Steele Laboratory for Tumor Biology at Massachusetts General Hospital. Dr. Snuderl joined the faculty at NYU Department of Pathology in January 2013 and has been actively involved in designing novel molecular tests and platforms particularly in molecular neuropathology and epigenetics. Dr. Snuderl participated in the development of the DNA methylation classifiers for brain tumors, sarcomas and other cancers. As the Director of Molecular Pathology at NYU, he clinically validated numerous molecular tests obtaining the first regulatory approval for DNA methylation and machine learning as diagnostic method in a CLIA laboratory as well as FDA 510(k) for the NYU Langone Genome PACT, the largest FDA cleared next-generation sequencing cancer test. His research interests include tumor genetics and epigenetics.